These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9816454)

  • 1. [Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-O157 Study in 224 patients (Germany)].
    Bachinger A; Kirchhoff D; Rychlik R
    Chirurg; 1998 Sep; 69(9):957-62. PubMed ID: 9816454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.
    Rabkin JM; Corless CL; Rosen HR; Olyaei AJ
    Transplant Proc; 2001; 33(1-2):1532-4. PubMed ID: 11267411
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506).
    Kramer MR; Merin G; Rudis E; Bar I; Nesher T; Bublil M; Milgalter E
    Transplant Proc; 1997 Sep; 29(6):2657-9. PubMed ID: 9290780
    [No Abstract]   [Full Text] [Related]  

  • 7. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
    Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
    Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study.
    Mühlbacher F;
    Transplant Proc; 2001; 33(1-2):1339-40. PubMed ID: 11267317
    [No Abstract]   [Full Text] [Related]  

  • 10. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
    Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
    Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine.
    Neylan JF; Sullivan EM; Steinwald B; Goss TF
    Am J Kidney Dis; 1998 Nov; 32(5):770-7. PubMed ID: 9820446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison].
    Guerra Junior AA; Acúrcio Fde A; Andrade EI; Cherchiglia ML; Cesar CC; Queiroz OV; Silva GD
    Cad Saude Publica; 2010 Jan; 26(1):163-74. PubMed ID: 20209220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC; Theilmann L
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract]   [Full Text] [Related]  

  • 20. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A.
    Bismuth H; Samuel D; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Groth C
    Transpl Int; 1994; 7 Suppl 1():S3-6. PubMed ID: 11271231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.